EU News
Printable version

Coronavirus: new procedure to facilitate and speed up approval of adapted vaccines against COVID-19 variants

Yesterday, as an immediate action under the HERA Incubator, the new European bio-defence preparedness plan against COVID-19 variants, the Commission is introducing a measure to speed up the authorisation of adapted COVID-19 vaccines. It will make provisions in the relevant EU legislation to allow companies to focus on gathering the necessary evidence in time and enable the authorisation of adapted vaccines with a smaller set of additional data submitted to the European Medicines Agency.

President of the European Commission, Ursula von der Leyen, yesterday said:

The HERA Incubator is to strengthen and accelerate the EU response to variants. We are enabling EMA to fast-track regulatory approval of updated vaccines to tackle new variants. Faster approval means more vaccines in circulation and more Europeans protected from the virus.”

Commissioner for Health and Food Safety, Stella Kyriakides yesterday said:

We need to be prepared to adapt vaccines as quickly as possible to respond to new and potentially vaccine-resistant variants. Today we propose fast and flexible solutions to fast-track approvals, without compromising on safety and efficacy. With the HERA Incubator, our goal is to anticipate and be one step ahead.”

Adaptations to active substances of an authorised COVID-19 vaccine may be required to ensure the vaccine's effectiveness against mutations or variants of a virus. Building on the approach for adaptations of human influenza – flu – vaccines, the changes to the Variation Regulation specify which provisions apply to adaptations of the active substance of authorised COVID-19 vaccines. These changes will ensure the streamlined handling of any variation to an authorised vaccine and extend the coverage of the new provisions to all coronaviruses.

The amendment provides a regulatory framework for the handling of changes to the marketing authorisation after the initial marketing authorisation.

Next Steps

As for any delegated regulation, the measure will now go to the European Parliament and Council for scrutiny before entering into force.

Click here for the full press release

 

Original article link: https://ec.europa.eu/commission/presscorner/detail/en/IP_21_1088

Share this article

Latest News from
EU News

Webinar: Enhancing Live Chat with MS Teams and AI to transform customer metrics